Dr. Jacob is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
750 E Adams St
Syracuse, NY 13210Phone+1 315-464-6106Fax+1 315-464-6117
Summary
- Dr. Joseph Jacob is an urologist in Syracuse, NY and is affiliated with multiple hospitals in the area, including Upstate University Hospital and Syracuse Veterans Affairs Medical Center. He received his medical degree from The Ohio State University College of Medicine and has been in practice 7 years. He specializes in surgical oncology and is experienced in testicular neoplasms, kidney neoplasms, urinary bladder neoplasms, and urologic neoplasms.
Education & Training
Indiana University School of MedicineFellowship, Minimally Invasive Urologic Surgery, 2015 - 2017
Indiana UniversityMCR, Clinical Research, 2015 - 2017- Indiana University School of MedicineResidency, Urology, 2010 - 2015
- Indiana University School of MedicineInternship, Surgery, 2010 - 2011
Ohio State University College of MedicineClass of 2010
Certifications & Licensure
NY State Medical License 2017 - 2025
PA State Medical License 2018 - 2018
IN State Medical License 2012 - 2017- American Board of Urology Urology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Start of enrollment: 2022 Mar 01
Roles: Contact
Publications & Presentations
PubMed
- 7 citationsEarly experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.Solomon L Woldu, Craig Labbate, Katie S Murray, Kyle Rose, Wade Sexton
Urologic Oncology. 2023-03-01 - 12 citationsRenal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy.Michael Daugherty, Emily C Daugherty, Joseph M. Jacob, Oleg Shapiro, Mehdi Mollapour
Urologic Oncology. 2019-03-01 - 22 citationsMultiresolution Application of Artificial Intelligence in Digital Pathology for Prediction of Positive Lymph Nodes From Primary Tumors in Bladder CancerStephanie Harmon, Thomas Sanford, G. Thomas Brown, Christopher Yang, Sherif Mehralivand
JCO Clinical Cancer Informatics. 2020-04-24
Press Mentions
TAR-200 Monotherapy Shows Greater Than 80% Complete Response Rate in Patients with High-Risk Non-Muscle-Invasive Bladder CancerMay 4th, 2024- TAR-200 Monotherapy Shows Greater Than 80 Percent Complete Response Rate in Patients with High-Risk Non-Muscle-Invasive Bladder CancerMay 7th, 2024
Committees
- Member, Cancer Center Clinical Management and Operations Committee 2017 - Present
Professional Memberships
- Member
- Society of Urologic OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
